ORIC Pharmaceuticals Announces Inducement Grants
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a dedicated clinical stage oncology company, is at the forefront of developing groundbreaking treatments aimed at overcoming therapeutic resistance in cancer. Recently, the company disclosed the issuance of inducement grants to a new non-executive officer, fueling excitement within the organization and the broader oncology community.
Details of the Inducement Grants
On a recent date, ORIC granted a substantial total of 292,500 non-qualified stock options along with 79,000 restricted stock units. This strategic move came shortly after the new employee joined ORIC in August 2025, showcasing the company’s commitment to attracting top talent in the competitive biopharmaceutical sector.
Understanding the Vesting Schedule
The stock options were granted solely as part of ORIC's 2022 Inducement Equity Incentive Plan. To emphasize the importance of retention, the grants are contingent upon the recipient maintaining employment through each vesting date. Specifically, 25% of the stock options are set to vest after one year, with the remainder being released at a steady pace thereafter. Meanwhile, the restricted stock units are structured to vest in a manner that rewards long-term commitment, with a third of these units vesting on each of the first three anniversaries of the grant date.
Approval from the Board of Directors
The Compensation Committee of ORIC's Board of Directors meticulously approved these grants, adhering to Nasdaq Rule 5635(c)(4). The decision emphasizes the importance of these inducement grants as a vital component in recruiting talent critical to the company's growth and innovation in oncology.
ORIC's Commitment to Oncology Innovations
ORIC Pharmaceuticals is passionately committed to transforming cancer treatment paradigms. They are focused on developing groundbreaking product candidates that aim to address significant unmet medical needs in the oncology landscape. Their lead candidates include ORIC-944, a potent allosteric inhibitor designed to target a critical component of the polycomb repressive complex 2 (PRC2) for treating prostate cancer. Another leading candidate, enozertinib (ORIC-114), is engineered to selectively act on EGFR and HER2 mutations, showcasing ORIC's dedication to precision medicine across various cancers.
Expanding Oncology Solutions
As ORIC advances through clinical trials, the company is steadfast in its goal to deliver novel therapies that offer hope to patients battling these complex diseases. Their focus on overcoming resistance mechanisms is not just an innovative approach; it aligns with their mission to enhance quality of life for patients affected by cancer.
Contact Information for ORIC Pharmaceuticals
If you wish to learn more about ORIC Pharmaceuticals and their ambitious plans, you can reach out to their Chief Financial Officer, Dominic Piscitelli, at dominic.piscitelli@oricpharma.com or contact info@oricpharma.com for general inquiries.
Frequently Asked Questions
What are the inducement grants announced by ORIC Pharmaceuticals?
The inducement grants include 292,500 non-qualified stock options and 79,000 restricted stock units given to a new employee as part of their compensation package.
What is the vesting schedule for the stock options?
The stock options will vest 25% after one year, with the remaining options vesting each month thereafter.
Who approved these inducement grants?
The grants were approved by the Compensation Committee of ORIC's Board of Directors, complying with Nasdaq regulations.
What is the focus of ORIC Pharmaceuticals?
ORIC Pharmaceuticals concentrates on developing innovative oncology therapies to overcome therapeutic resistance in cancer treatments.
How can I contact ORIC Pharmaceuticals for more information?
You can contact Dominic Piscitelli at dominic.piscitelli@oricpharma.com for inquiries or general information can be directed to info@oricpharma.com.
